Get the Stockscreener App
1.31
1.50%
-0.02
After Hours:
1.31
Cardiol Therapeutics Inc stock is traded at $1.31, with a volume of 438.13K.
It is down -1.50% in the last 24 hours and down -7.09% over the past month.
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
See More
Previous Close:
$1.33
Open:
$1.32
24h Volume:
438.13K
Relative Volume:
0.67
Market Cap:
$146.30M
Revenue:
-
Net Income/Loss:
$-24.22M
P/E Ratio:
-4.6802
EPS:
-0.2799
Net Cash Flow:
$-17.13M
1W Performance:
-4.38%
1M Performance:
-7.09%
6M Performance:
+20.18%
1Y Performance:
+13.91%
1-Day Range:
$1.28
$1.36
1-Week Range:
$1.28
$1.395
52-Week Range:
$0.88
$1.71
Cardiol Therapeutics Inc Stock (CRDL) Company Profile
Compare CRDL vs TAK, ZTS, TEVA, HLN, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRDL
Cardiol Therapeutics Inc
|
1.31 | 148.53M | 0 | -24.22M | -17.13M | -0.2799 |
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.54 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.86 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.17 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
572.20 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
Cardiol Therapeutics Inc Stock (CRDL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Initiated | H.C. Wainwright | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jun-26-24 | Initiated | ROTH MKM | Buy |
| Apr-22-24 | Initiated | H.C. Wainwright | Buy |
Cardiol Therapeutics Inc Stock (CRDL) Latest News
CRDL.CA Stock Price, Quote & Chart | CARDIOL THERAPEUTICS INC-A (TSX:CRDL) - ChartMill
Phase III Trial Enrollment Reached (75%) for Promising Anti-Inflammatory and Anti-Fibrotic Cardiac Therapies by Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) - Barchart.com
Phase III Trial Enrollment Reached (75%) for Promising - openPR.com
User - The Chronicle-Journal
MSN Money - MSN
Cardiol Therapeutics (CRDL) Expands MAVERIC Trial with New Clini - GuruFocus
Cardiol Therapeutics expands Phase III trial to 25 sites By Investing.com - Investing.com India
Cardiol Therapeutics Inc. - Baystreet.ca
Stocks in play: Cardiol Therapeutics Inc. - Barchart.com
Cardiol Therapeutics expands Phase III trial to 25 sites - Investing.com UK
Cardiol Therapeutics Expands U.S. Phase III MAVERIC Trial Network as Enrollment Reaches 75% - TipRanks
Cardiol Therapeutics (NASDAQ: CRDL) expands U.S. MAVERIC Phase III trial network - Stock Titan
Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program - ChartMill
Ellis Martin Report: Cardiol Therapeutics (TSE.CRDL) CEO David Elsley on Breakthrough Heart Disease Treatment - ABN Newswire
Correction: Positive Results on MAVERIC Phase 2 and Published ARCHER Study Presented by the Company CEO in Live Interview with Barchart: Cardiol Therapeutics Inc. (NASDAQ: CRDL) - Barchart.com
Correction: Positive Results on MAVERIC Phase 2 and Published - openPR.com
Positive Results on MAVERIC Phase III Trial and Published ARCHER Study Presented by the Company CEO in Live Interview with Barchart: Cardiol Therapeutics Inc. (NASDAQ: CRDL) - Barchart
Positive Results on MAVERIC Phase III Trial and Published ARCHER - openPR.com
CRDL (Cardiol Therapeutics Inc.) Q4 2025 narrower than expected loss lifts shares more than 7 percent higher today.Revenue Diversification - Xã Thanh Hà
Is Cardiol (CRDL) stock sensitive to volatility (Drops Sharply) 2026-04-22Investment Community Signals - Cổng thông tin điện tử tỉnh Lào Cai
Metro Q2 2026 Earnings Rise On Margins, Buybacks And Pharmacy Growth - thedeepdive.ca
Moderna to Present at Upcoming Conferences in May 2026 - Investing News Network
Cardiol Therapeutics (TSE:CRDL) Sets New 1-Year HighHere's Why - MarketBeat
CRDL Stock Price, Quote & Chart | CARDIOL THERAPEUTICS INC-A (NASDAQ:CRDL) - ChartMill
Fixing Heart Disease Tied to Sudden Death in Young People | David ElsleyCardiol Therapeutics - thedeepdive.ca
Cardiol Therapeutics (TSE:CRDL) Trading Up 7.9%Here's What Happened - MarketBeat
Cardiol Therapeutics CEO: Phase III MAVERIC Nears Full Enrollment as CardiolRx Shows Myocarditis Promise - MarketBeat
Cardiol Therapeutics CEO to discuss drug trials in interview By Investing.com - Investing.com Australia
Cardiol Therapeutics CEO to discuss drug trials in interview - Investing.com
Cardiol Therapeutics Showcases MAVERIC Phase III Trial and ARCHER Results in Barchart Live Interview - TipRanks
Cardiol Therapeutics (CRDL) CEO to discuss MAVERIC, ARCHER and CRD-38 in X interview - Stock Titan
Cardiol CEO goes live on X to discuss Phase III heart drug trial - Stock Titan
Cardiol Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
$30 Billion Per Year US Heart Failure Market Presents Huge Opportunity for Promising Drugs Advancing with Positive Trial Results for Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) - Barchart
$30 Billion Per Year US Heart Failure Market Presents Huge - openPR.com
Top Athira Pharma (LONA) Competitors 2026 - MarketBeat
Earnings Report: Is Cardiol Therapeutics Inc a cyclical or defensive stock2026 Pullback Review & High Yield Equity Trading Tips - baoquankhu1.vn
Cardiol Therapeutics Sets June 24, 2026 Date for Annual General Meeting of Shareholders - The Globe and Mail
3 Biotech Stocks Surge with Momentum - National Today
Cardiol Therapeutics (CRDL) sets June 24, 2026 AGM and May 7 record date - Stock Titan
Risk Off: Should I trade or invest in Cardiol Therapeutics Inc2026 Biggest Moves & Precise Trade Entry Recommendations - baoquankhu1.vn
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE), Alzamend Neuro (ALZN) and Cardiol Therapeutics (CRDL) - The Globe and Mail
Cardiol Therapeutics Secures Funding Through 2027 Amid Clinical Advancements - AD HOC NEWS
CRDL Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Research Analysts Set Expectations for CRDL Q3 Earnings - MarketBeat
Cardiol Therapeutics (CRDL) Receives 'Buy' Rating from Canaccord Genuity | CRDL Stock News - GuruFocus
Cardiol Therapeutics (NASDAQ:CRDL) Earns "Buy" Rating from Canaccord Genuity Group - MarketBeat
Cardiol Therapeutics: A 2026 Inflection Point on the Horizon - AD HOC NEWS
Cardiol Therapeutics (NASDAQ:CRDL) Raised to Hold at Wall Street Zen - MarketBeat
Cardiol Therapeutics Inc Stock (CRDL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.67%
2.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):